Business Context and Reporting Period
This Form 8-K is filed by Biorestorative Therapies, Inc., a Delaware corporation and emerging growth company. The report covers events occurring between December 26, 2019, and January 7, 2020, with the report date listed as December 31, 2019.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or operating margins. The primary financial data disclosed relates to a specific debt settlement transaction:
- Debt Settled: $158,192 (inclusive of accrued and unpaid interest).
- Equity Issued: 56,225,589 shares of common stock.
- Transaction Type: Unregistered sales of equity securities in exchange for outstanding indebtedness.
Material Changes
The material change reported is the conversion of approximately $158,192 in outstanding debt into 56,225,589 shares of common stock. This transaction significantly altered the company's capital structure by reducing liabilities and increasing the number of outstanding shares. The filing does not provide comparative data to the prior period for general financial performance.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the transaction mechanics. The company relied on Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933 for the exemption from registration, asserting that the securities were offered to a limited number of accredited investors without general solicitation.
Investor Verification Checklist
- Verify the total number of outstanding shares post-transaction to assess dilution impact.
- Confirm the remaining outstanding debt balance after the $158,192 settlement.
- Review the company's liquidity position in the most recent Form 10-K or 10-Q, as this 8-K does not provide cash flow data.
- Check for any subsequent filings regarding the valuation of the shares issued or the terms of the original debt.